<DOC>
	<DOCNO>NCT02311140</DOCNO>
	<brief_summary>The aim propose trial assessment effect Kalydeco™ treatment sinonasal involvement CF patient least one mutation G551D receive new therapy CFTR potentiator . The focus give change epithelial line fluid inflammatory marker CF upper airway sample nasal lavage . The program subdivide part A assess inflammatory marker NL sinonasal symptom longitudinally pre-treatment month new therapy . Part B perform small subgroup ass inflammatory marker NL every second day first month treatment every week end month 3 Kalydeco™ therapy .</brief_summary>
	<brief_title>Effects Kalydeco Upper Airway Paranasal Sinus Inflammation Measured Nasal Lavage Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<criteria>G551D Kalydeco therapy G551D</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>nasal lavage</keyword>
	<keyword>inflammation</keyword>
	<keyword>Interleukin ( IL ) -6</keyword>
	<keyword>IL-8</keyword>
	<keyword>pulmonary function</keyword>
</DOC>